ArticleHereditary cancer in clinical practice2026
Utilization of care and alignment of screening with NCCN guidelines for patients with Lynch syndrome: a retrospective cohort study.
Article in Hereditary cancer in clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pan-cancer prevalence of microsatellite instability and Lynch syndrome in India.Familial cancer · 2026Article
- Factors Associated with Adherence to Recommended Colorectal Surveillance Intervals in Lynch Syndrome.Cancers · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesDetermine the proportion of patients with Lynch syndrome who received guideline-concordant care according to NCCN guidelines during the study period (2015–2018).
methodsA retrospective cohort study was performed at Kaiser Permanente Northern California including patients with germline pathogenic variants in MLH1, MSH2/EPCAM, MSH6 or PMS2 tested between 01/01/2015 and 12/31/2018. Clinical and demographic characteristics were abstracted from chart review. Screenings were assessed for gynecologic, gastrointestinal (GI), urinary, skin, and neurologic cancer sites. Concordance was assessed against NCCN guidelines (versions 1.2015 through 1.2018) matched to the year of each patient encounter. The primary outcome was receipt of guideline-concordant care. Secondary outcomes included rates of under- and over-utilization and clinical/demographic factors associated with care utilization.
resultsWe identified 234 patients: 46 with pathogenic MLH1 variants, 64 with MSH6, 83 with PMS2 and 41 with MSH2/EPCAM variants. Median age was 52 years (IQR: 39–62), most were white (60%) and 29% were tested based on a personal cancer history. Half (48%) of patients received screening as recommended by NCCN guidelines, with highest concordance for GI cancer screening. A quarter of patients received less screening than recommended by guidelines. Patients with MLH1 variants had higher rates of transvaginal ultrasound (34.2%) and urologic cancer screening (28.3%) compared to those with other variants.
conclusionsOnly 48% of patients in this integrated healthcare system received guideline-concordant Lynch syndrome surveillance. Our findings highlight variation in screening practices across pathogenic variant types and suggest opportunities for improving adherence to recommended screenings within healthcare systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.